GURUFOCUS.COM » STOCK LIST » Financial Services » Credit Services » Pegasus Mercantile Inc (XCNQ:LOAN) » Definitions » Debt-to-EBITDA

Pegasus Mercantile (XCNQ:LOAN) Debt-to-EBITDA : -0.05 (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Pegasus Mercantile Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pegasus Mercantile's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$0.00 Mil. Pegasus Mercantile's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$0.02 Mil. Pegasus Mercantile's annualized EBITDA for the quarter that ended in Dec. 2024 was C$-0.37 Mil. Pegasus Mercantile's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pegasus Mercantile's Debt-to-EBITDA or its related term are showing as below:

XCNQ:LOAN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.12   Med: -0.05   Max: -0.02
Current: -0.04

During the past 13 years, the highest Debt-to-EBITDA Ratio of Pegasus Mercantile was -0.02. The lowest was -0.12. And the median was -0.05.

XCNQ:LOAN's Debt-to-EBITDA is ranked worse than
100% of 272 companies
in the Credit Services industry
Industry Median: 8.475 vs XCNQ:LOAN: -0.04

Pegasus Mercantile Debt-to-EBITDA Historical Data

The historical data trend for Pegasus Mercantile's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pegasus Mercantile Debt-to-EBITDA Chart

Pegasus Mercantile Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.02 -0.02 -0.07 -0.12

Pegasus Mercantile Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.06 -0.04 -0.11 -0.05

Competitive Comparison of Pegasus Mercantile's Debt-to-EBITDA

For the Credit Services subindustry, Pegasus Mercantile's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pegasus Mercantile's Debt-to-EBITDA Distribution in the Credit Services Industry

For the Credit Services industry and Financial Services sector, Pegasus Mercantile's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pegasus Mercantile's Debt-to-EBITDA falls into.


;
;

Pegasus Mercantile Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pegasus Mercantile's Debt-to-EBITDA for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.059 + 0.018) / -0.624
=-0.12

Pegasus Mercantile's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.018) / -0.368
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Pegasus Mercantile  (XCNQ:LOAN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pegasus Mercantile Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pegasus Mercantile's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pegasus Mercantile Business Description

Traded in Other Exchanges
Address
1100 - 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6
Pegasus Mercantile Inc is a debt financing company. The company provides high-growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp, and CBD, healthcare-related target companies, and its clinical studies and trials.